European Monitoring Centre for Drugs and Drug Addiction. (2018) Report on the risk assessment of N-(4-fluorophenyl)-2-methyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide (4-fluoroisobutyrylfentanyl 4F-iBF), in the framework of the Council Decision on new psychoactive substances. Risk Assessments. Luxembourg: Publications Office of the European Union.
Preview | Title | Contact |
---|---|---|
|
PDF (Risk assessment 4F-iBF)
- Published Version
1MB |
This publication presents the data and findings of the risk assessment on N-(4-fluorophenyl)-2-methyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide (4F-iBF), carried out by the extended Scientific Committee of the EMCDDA on 7-8 November 2017. In March 2018, at its 61st regular session, the Commission on Narcotic Drugs (CND) decided to place 4F-iBF in Schedule I of the Single Convention on Narcotic Drugs of 1961 based on a recommendation by the World Health Organization. This recommendation was substantially supported by European data provided by the EMCDDA.
Repository Staff Only: item control page